Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
135 hedge funds and large institutions have $1.04B invested in Keryx Biopharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 49 increasing their positions, 46 reducing their positions, and 32 closing their positions.
20% more call options, than puts
Call options by funds: $19M | Put options by funds: $15.8M
7% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
9% less capital invested
Capital invested by funds: $1.14B → $1.04B (-$107M)
10% less funds holding
Funds holding: 150 → 135 (-15)
44% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$59.9M |
| 2 |
DM
Deerfield Management
New York
|
+$35.2M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$24.8M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$6.4M |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$3.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$38.6M |
| 2 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
-$22.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$10M |
| 4 |
ICRM
Insight Capital Research & Management
Walnut Creek,
California
|
-$10M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$6.44M |
KERX Hedge Fund Activity: Q2 2014 in Review
135 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q2 2014, worth a combined $1.04B — down 9.3% from $1.14B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of KERX and 18 opened new positions — a net loss of 14 holders — while 46 trimmed existing stakes and 49 added.
The largest buyer was Baupost Group, adding an estimated $59.9M. The largest seller was Wells Fargo, cutting an estimated $38.6M.
- 135 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q2 2014, down from 150 in Q1 2014.
- Funds reported $1.04B of Keryx Biopharmaceuticals Inc stock for Q2 2014, down 9.3% quarter-over-quarter.
- 18 funds opened new Keryx Biopharmaceuticals Inc positions in Q2 2014 and 32 closed out, a net change of -14 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q2 2014 was Baupost Group, an estimated $59.9M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q2 2014 was Wells Fargo, an estimated $38.6M sold.
Based on aggregated 13F filings for Q2 2014.